Both in Pharmaceuticals
Gyre Therapeutics vs Arvinas
Over the past year GYRE returned −39.6% and ARVN returned −24.0%; their daily moves had a correlation of 0.18.
GYRE −39.6% ARVN −24.0%Growth of $1, one year, split-adjusted
| Metric | GYRE | ARVN |
|---|---|---|
| Price | $4.45 | $7.39 |
| Market cap | $471.3M | $483.2M |
| Today | +0.11% | +4.23% |
| 1 month | −37.2% | +1.1% |
| 6 months | −44.7% | −28.0% |
| Year to date | −37.0% | −37.7% |
| 1 year | −39.6% | −24.0% |
| Revenue growth (YoY) | −2.1% | +1014.7% |
| Gross margin | 92.4% | 96.4% |
| Net margin | −40.1% | 67.8% |
| P/E (TTM) | — | 52.0× |
| Price / sales | 3.9× | 1.5× |
| Net cash | $74.8M | $567.6M |
| Dividend yield | — | — |
| Volatility (60d) | 88.3% | 49.2% |
| Short % of float | 11.5% | 10.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).